Teva Moves Toward Biogenerics Goal With CoGenesys Acquisition

Israeli generics maker pays $400 million for the biopharma, which brings an advanced drug development platform called Albumin Fusion.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet